← All Ibio, INC filings

Ibio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IBIO
Ibio, INC
10-K: iBio's AI-Driven Obesity Pipeline Advances, Secures $46.5M
iBio, a preclinical biotechnology company, is leveraging AI to develop precision antibodies for cardiometabolic and obesity diseases, advancing key candidates and securing significant capital.
NASDAQ
IBIO
Ibio, INC
10-K/A: iBio, Inc. Amends Annual Report, Corrects Typographical Error in Auditor's Report
iBio, Inc. has filed an amendment to its annual report to correct a typographical error in the signature date of the independent auditor's report.
NASDAQ
IBIO
Ibio, INC
10-K: iBio, Inc. Leverages AI for Precision Antibody Development in Fiscal Year 2024
iBio, Inc. transitioned to an AI-powered biotech company focused on precision antibody development, divesting its CDMO facility and forming strategic collaborations.